The correspondents describe the successful use of denosumab, a monoclonal antibody that inhibits receptor activator of nuclear factor-κB ligand, to control hypercalcemia after hematopoietic stem-cell transplantation in two children with osteopetrosis.
No takes yet. Share an insight, caveat, or question.
Shroff et al. (2012) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: